Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH. Dooley KE, et al. Among authors: vanker n. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1579-1580. doi: 10.1164/rccm.202002-0359LE. Am J Respir Crit Care Med. 2020. PMID: 32130866 Free PMC article. No abstract available.
Optimizing β-Lactams against Tuberculosis.
de Jager VR, Vanker N, van der Merwe L, van Brakel E, Muliaditan M, Diacon AH. de Jager VR, et al. Among authors: vanker n. Am J Respir Crit Care Med. 2020 May 1;201(9):1155-1157. doi: 10.1164/rccm.201911-2149LE. Am J Respir Crit Care Med. 2020. PMID: 31922901 Free PMC article. No abstract available.
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH; A5312 Study Team. Dooley KE, et al. Among authors: vanker n. Am J Respir Crit Care Med. 2020 Jun 1;201(11):1416-1424. doi: 10.1164/rccm.201910-1960OC. Am J Respir Crit Care Med. 2020. PMID: 31945300 Free PMC article.
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
Diacon AH, De Jager VR, Dawson R, Narunsky K, Vanker N, Burger DA, Everitt D, Pappas F, Nedelman J, Mendel CM. Diacon AH, et al. Among authors: vanker n. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02012-19. doi: 10.1128/AAC.02012-19. Print 2020 Mar 24. Antimicrob Agents Chemother. 2020. PMID: 31988102 Free PMC article. Clinical Trial.
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills GH, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M; Nix-TB Trial Team. Conradie F, et al. N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814. N Engl J Med. 2020. PMID: 32130813 Free PMC article. Clinical Trial.
Telacebec (Q203), a New Antituberculosis Agent.
de Jager VR, Dawson R, van Niekerk C, Hutchings J, Kim J, Vanker N, van der Merwe L, Choi J, Nam K, Diacon AH. de Jager VR, et al. Among authors: vanker n. N Engl J Med. 2020 Mar 26;382(13):1280-1281. doi: 10.1056/NEJMc1913327. N Engl J Med. 2020. PMID: 32212527 Clinical Trial. No abstract available.
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".
Diacon AH, De Jager VR, Dawson R, Narunsky K, Vanker N, Burger DA, Everitt D, Pappas F, Nedelman J, Mendel CM. Diacon AH, et al. Among authors: vanker n. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00709-20. doi: 10.1128/AAC.00709-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32366714 Free PMC article. No abstract available.
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis.
Xie YL, de Jager VR, Chen RY, Dodd LE, Paripati P, Via LE, Follmann D, Wang J, Lumbard K, Lahouar S, Malherbe ST, Andrews J, Yu X, Goldfeder LC, Cai Y, Arora K, Loxton AG, Vanker N, Duvenhage M, Winter J, Song T, Walzl G, Diacon AH, Barry CE 3rd. Xie YL, et al. Among authors: vanker n. Sci Transl Med. 2021 Feb 3;13(579):eabd7618. doi: 10.1126/scitranslmed.abd7618. Sci Transl Med. 2021. PMID: 33536283 Free PMC article.
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin.
Te Brake LHM, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PPJ, Gillespie SH, Heinrich N, Hoelscher M, Dawson R, Diacon AH, Aarnoutse RE, Boeree MJ; PanACEA Consortium. Te Brake LHM, et al. Among authors: vanker n. Eur Respir J. 2021 Jul 8;58(1):2000955. doi: 10.1183/13993003.00955-2020. Print 2021 Jul. Eur Respir J. 2021. PMID: 33542056 Free PMC article.
19 results